The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Managing bispecific T-cell engager toxicity in lung cancer
Martin Schuler, MD, University Hospital Essen, Essen, Germany, outlines strategies for managing cytokine release syndrome (CRS) and ICANS in patients receiving bispecific T-cell engagers for solid tumors. He emphasizes proactive patient education, dexamethasone premedication, and rapid intervention for immune-related toxicities. Compared to CAR T-cell therapy, these adverse events are typically mild, occur early during initial dosing, and are well controlled with standard supportive care. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
